Patents by Inventor Michael Diem

Michael Diem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prostate specific membrane antigen binding fibronectin type iii domains
    Patent number: 12054534
    Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: August 6, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rosa Cardoso, Michael Diem, Shalom Goldberg, Linus Hyun, Steven Jacobs, Donna Klein, Karyn O'Neil, Tracy Spinka-Doms
  • Serum Albumin-Binding Fibronectin Type III Domains
    Publication number: 20240100129
    Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
    Type: Application
    Filed: October 27, 2023
    Publication date: March 28, 2024
    Inventors: Michael Diem, Steven Jacobs, Karyn O'Neil, Thomas Rutkoski
  • MATERIALS AND METHODS FOR IMPROVED SINGLE CHAIN VARIABLE FRAGMENTS
    Publication number: 20240067754
    Abstract: Disclosed are materials and methods for improved single chain variable fragments.
    Type: Application
    Filed: September 5, 2023
    Publication date: February 29, 2024
    Inventors: Jinquan LUO, Lauren BOUCHER, Michael FELDKAMP, Michael DIEM, Anthony A. ARMSTRONG, Alexey TEPLYAKOV, Chichi HUANG
  • Serum albumin-binding fibronectin type III domains
    Patent number: 11833190
    Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: December 5, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Michael Diem, Steven Jacobs, Karyn O'Neil, Thomas Rutkoski
  • Materials and methods for improved single chain variable fragments
    Patent number: 11787875
    Abstract: Disclosed are materials and methods for improved single chain variable fragments.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: October 17, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Jinquan Luo, Lauren Boucher, Michael Feldkamp, Michael Diem, Anthony A. Armstrong, Alexey Teplyakov, Chichi Huang
  • Underframe for a Rail Vehicle Car Body
    Publication number: 20230159066
    Abstract: An underframe for a rail vehicle car body includes a plurality of longitudinal support members oriented in the longitudinal direction of the underframe, and at least one transverse support member which, in the fitted position is oriented perpendicular to the longitudinal support members, wherein the longitudinal support members each have an opening at the level of the mounting position of the transverse member through which the transverse member can be inserted.
    Type: Application
    Filed: April 21, 2021
    Publication date: May 25, 2023
    Inventors: Clemens EGER-HÜBEL, Michael DIEM
  • BIOSYNTHETIC GLYCOPROTEIN POPULATIONS
    Publication number: 20220356266
    Abstract: A population of antibodies, wherein less than 80% of the oligosaccharides covalently attached to the population of the antibodies via N297 residues thereof comprise a core fucose residue; and wherein the population of the antibodies comprises an antibody which Fc region comprises K338A and T437R mutations, or K248E and T437R mutations.
    Type: Application
    Filed: April 16, 2021
    Publication date: November 10, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar GANESAN, Adam ZWOLAK, Jason HO, Natasa OBERMAJER, Michael DIEM, Sanjaya SINGH, Sathyadevi VENKATARAMANI, Theresa MCDEVITT, Fei SHEN
  • Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and uses thereof
    Patent number: 11466082
    Abstract: Anti-CD33 antibodies and antigen-binding fragments thereof and anti-CD33/anti-CD3 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: October 11, 2022
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Michael Diem, Francois Gaudet, Ronan McDaid, Priyanka Nair-Gupta
  • PD-L1 binding fibronectin type III domains
    Patent number: 11447539
    Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: September 20, 2022
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • CD137 BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20220259289
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: April 28, 2022
    Publication date: August 18, 2022
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • CD137 binding fibronectin type III domains
    Patent number: 11345739
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: May 31, 2022
    Assignee: JANSSEN BIOTECH, INC
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Serum Albumin-Binding Fibronectin Type III Domains
    Publication number: 20210228688
    Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
    Type: Application
    Filed: January 20, 2021
    Publication date: July 29, 2021
    Inventors: Michael Diem, Steven Jacobs, Karyn O'Neil, Thomas Rutkoski
  • EGFR and C-Met Fibronectin Type III Domain Binding Molecules
    Publication number: 20210206825
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Application
    Filed: February 12, 2021
    Publication date: July 8, 2021
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20210147510
    Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Application
    Filed: October 13, 2020
    Publication date: May 20, 2021
    Inventors: Rosa Cardoso, Michael Diem, Shalom Goldberg, Linus Hyun, Steven Jacobs, Donna Klein, Karyn O'Neil, Tracy Spinka-Doms
  • EGFR and c-Met fibronectin type III domain binding molecules
    Patent number: 10954284
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 23, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • Serum albumin-binding fibronectin type III domains
    Patent number: 10925932
    Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: February 23, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Michael Diem, Steven Jacobs, Karyn O'Neil, Thomas Rutkoski
  • MATERIALS AND METHODS FOR IMPROVED SINGLE CHAIN VARIABLE FRAGMENTS
    Publication number: 20210047435
    Abstract: Disclosed are materials and methods for improved single chain variable fragments.
    Type: Application
    Filed: August 14, 2020
    Publication date: February 18, 2021
    Inventors: Jinquan Luo, Lauren Boucher, Michael Feldkamp, Michael Diem, Anthony A. Armstrong, Alexey Teplyakov, Chichi Huang
  • CD137 Binding Fibronectin Type III Domains
    Publication number: 20210040180
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: March 17, 2020
    Publication date: February 11, 2021
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20210024612
    Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: February 26, 2020
    Publication date: January 28, 2021
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Prostate specific membrane antigen binding fibronectin type III domains
    Patent number: 10844111
    Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 24, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Rosa Cardoso, Michael Diem, Shalom Goldberg, Linus Hyun, Steven Jacobs, Donna Klein, Karyn O'Neil, Tracy Spinka-Doms